Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:ATHA OTCMKTS:OSIR NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.00$3.61$2.71▼$7.34$124.93M1.57614,147 shs867,833 shsATHAAthira Pharma$8.22-4.5%$9.26$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$63.16$63.18$38.51▼$85.25$2.72B0.49567,922 shs402,143 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus0.00%-9.09%-5.06%-19.14%-32.89%ATHAAthira Pharma0.00%0.00%-14.55%-17.14%+165.16%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals0.00%+1.95%-0.50%-2.09%+53.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.00$3.61$2.71▼$7.34$124.93M1.57614,147 shs867,833 shsATHAAthira Pharma$8.22-4.5%$9.26$0.23▼$8.36$32.42M2.79602,475 shs15,987 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$63.16$63.18$38.51▼$85.25$2.72B0.49567,922 shs402,143 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus0.00%-9.09%-5.06%-19.14%-32.89%ATHAAthira Pharma0.00%0.00%-14.55%-17.14%+165.16%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals0.00%+1.95%-0.50%-2.09%+53.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.00Hold$23.00666.67% UpsideATHAAthira Pharma 1.00Sell$4.00-51.34% DownsideOSIROsiris Therapeutics 0.00N/AN/AN/ATARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6743.55% UpsideCurrent Analyst Ratings BreakdownLatest ATHA, TARS, AGEN, and OSIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026AGENAgenus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/11/2026AGENAgenus Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/4/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/24/2026TARSTarsus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$105.00 ➝ $98.004/21/2026TARSTarsus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026AGENAgenus Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$114.20M1.09N/AN/A($8.17) per share-0.37ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals$451.36M6.02N/AN/A$8.09 per share7.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus$120K$1.591.89N/AN/A50.49%-31.66%42.71%8/10/2026 (Estimated)ATHAAthira Pharma-$96.94M-$9.68N/AN/AN/AN/A-107.06%-89.89%N/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$66.42M-$1.14N/A21.63N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest ATHA, TARS, AGEN, and OSIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026AGENAgenus$2.10$1.02-$1.08$1.02$129.50 million$33.74 million5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.380.38ATHAAthira PharmaN/A9.709.70OSIROsiris TherapeuticsN/AN/AN/ATARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%ATHAAthira Pharma57.12%OSIROsiris Therapeutics0.28%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipAGENAgenus6.50%ATHAAthira Pharma19.80%OSIROsiris Therapeutics43.40%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44041.64 million38.94 millionOptionableATHAAthira Pharma403.94 million3.16 millionNo DataOSIROsiris Therapeutics34234.53 millionN/ANot OptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableATHA, TARS, AGEN, and OSIR HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Lowered by Wall Street ZenJune 20 at 1:30 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Downgraded by Wall Street Zen to HoldJune 20 at 1:29 AM | marketbeat.comTarsus: Not Cheap, But Xdemvy Makes The Valuation WorkJune 19 at 1:46 AM | seekingalpha.comTarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $183,384.32 in StockJune 18 at 8:13 AM | insidertrades.comIshara Investments LP Purchases Shares of 24,000 Tarsus Pharmaceuticals, Inc. $TARSJune 18 at 6:12 AM | marketbeat.comCormorant Asset Management LP Lowers Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 18 at 5:00 AM | marketbeat.comTarsus Pharmaceuticals Inc.June 16, 2026 | barrons.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Sands Capital Alternatives LLCJune 15, 2026 | marketbeat.comFrazier Life Sciences Management L.P. Sells 438,883 Shares of Tarsus Pharmaceuticals, Inc. $TARSJune 14, 2026 | marketbeat.comA Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived DiscountJune 10, 2026 | finance.yahoo.comClearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARSJune 10, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street ZenJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $29.16 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 5, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 2, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMJohn Cena hops into the ring to fight demodex blepharitis for Tarsus PharmaceuticalsMay 19, 2026 | mmm-online.comMTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicrosoft Just Gave Investors 3 Dates They Can't Afford to IgnoreBy Chris Markoch | June 11, 2026Apple’s Agentic AI Plans Could Be Its Biggest Growth Story YetBy Sam Quirke | May 29, 2026AI Can’t Reach the Real World Without These 3 StocksBy Thomas Hughes | May 27, 2026Cloud-flation: Dell's On-Premise AI Bet Pays OffBy Jeffrey Neal Johnson | May 26, 2026Salesforce Stock Finds Support as AI Momentum BuildsBy Thomas Hughes | May 29, 2026ATHA, TARS, AGEN, and OSIR Company DescriptionsAgenus NASDAQ:AGEN$3.00 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.63%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Athira Pharma NASDAQ:ATHA$8.22 -0.39 (-4.53%) As of 06/5/2026Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Tarsus Pharmaceuticals NASDAQ:TARS$63.16 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$63.20 +0.04 (+0.06%) As of 06/18/2026 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
